New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
04:55 EDTGSK, GSK, AEP, AEP, MS, MS, MIC, MIC, TROW, TROW, BAC, BACEdison Electric Institute to hold a conference
International Utility Conference is being held in London, England on March 10-11.
News For GSK;AEP;MS;MIC;TROW;BAC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 14, 2015
06:04 EDTMSUnivision IPO could launch 'in weeks,' NY Post reports
Subscribe for More Information
May 13, 2015
11:38 EDTGSKGlaxoSmithKline downgraded to Neutral from Buy at UBS
Subscribe for More Information
09:39 EDTBACActive equity options trading on open
Subscribe for More Information
09:32 EDTMSMorgan Stanley fined $2M by FINRA for short interest reporting, rule violations
FINRA announced that it has fined Morgan Stanley & Co. LLC $2M for short interest reporting and short sale rule violations that spanned a period of more than six years, and for failing to implement a supervisory system reasonably designed to detect and prevent such violations. FINRA found that Morgan Stanley, over several years, failed to completely and accurately report its short interest positions in certain securities involving billions of shares. FINRA also found that the firm's supervisory system was deficient because it failed to detect and prevent these violations over an extended period of time. FINRA found that over a seven-year period, Morgan Stanley included positions from the accounts of non-broker-dealer affiliates in a number of aggregation units when determining each unit's net position. FINRA also found that the firm's supervisory system was not reasonably designed to detect and prevent such violations. In concluding this settlement, Morgan Stanley neither admitted nor denied the charges, but consented to the entry of FINRA's findings.
07:29 EDTBACUBS to hold a conference
Subscribe for More Information
07:07 EDTGSKGSK, Emergent BioSolutions, Oxford initiate Prime Boost study of Ebola vaccine
A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara, or MVA, Ebola Zaire vaccine candidate, or MVA EBOZ, as a prime-boost to GlaxoSmithKline's (GSK) Chimp Adenovirus type 3, or ChAd3, Ebola vaccine candidate. The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom's Medicines and Healthcare Products Regulatory Agency, or MHRA. The phase 1 study has a planned enrollment of 38 volunteers of which 6 will receive MVA EBOZ only while the other 32 will receive ChAd3-EBO-Z prime followed by MVA EBOZ boost. Emergent BioSolutions (EBS) manufactured the supply of MVA EBOZ to be used in this phase 1 study, which is being conducted in the U.K. with support from the Wellcome Trust and the U.K. Department for International Development.
May 12, 2015
14:13 EDTBAC, MSBove says it may be time to buy bank stocks
Subscribe for More Information
07:48 EDTMSStandard & Poor's to hold a summit
Subscribe for More Information
07:37 EDTMICOppenheimer to hold a conference
10th Annual Industrial Growth Conference is being held in New York on May 12-13 with webcasted company presentations to begin on May 12 at 8:15 am; not all company presentations may be webcasted. Webcast Link
06:02 EDTGSKGSK CEO cites 'poor choices' in rivals' M&A deals, Financial Times reports
Subscribe for More Information
May 11, 2015
17:02 EDTMSMorgan Stanley to sell Global Oil Merchanting unit to Castleton Commodities
Subscribe for More Information
16:00 EDTBACOptions Update; May 11, 2015
Subscribe for More Information
15:54 EDTGSKGlaxo CEO defends strategy, warns of risks of chasing higher prices, FT says
GlaxoSmithKline (GSK) CEO Andrew Witty defends the company's shift in focus from high-priced prescription drugs to higher volume, but lower priced, products, warning that chasing ever-higher prices risks undermining the industry and may create "its own tension that leads to some kind of change,” reported Financial Times, citing an interview. Witty acknowledges the company's asset swap with Novartis (NVS) opens the door to a potential break up, but argues there are benefits to keeping pharmaceuticals, vaccines and consumer goods together and there would be “no logic” in a split at this early time after the Novartis deal, the report added. Reference Link
12:51 EDTMSOn The Fly: Top stock stories at midday
Subscribe for More Information
09:58 EDTBACBarclays expected to pay GBP2B to settle forex rigging charges, FT says
Subscribe for More Information
09:37 EDTBACActive equity options trading on open
Subscribe for More Information
08:18 EDTMS, BACBanks executives seek to push back on 'false, damaging' statements, WSJ reports
Subscribe for More Information
07:07 EDTMSMorgan Stanley announces sale of Creative Circle to On Assignment
Subscribe for More Information
05:58 EDTGSKUNC, GlaxoSmithKline create dedicated HIV Cure center
Subscribe for More Information
May 10, 2015
12:54 EDTAEPDuke, Edison, other utilities could return 8% annually, Barron's says
Shares of Duke Energy (DUK), Southern Company (SO), Consolidated Edison (ED), Edison International (EIX), PG&E (PCG), American Electric (AEP), Dominion (D), and NextEra Energy (NEE) could return 8% or more annually in coming years, Barron's contends in a feature article. Though utilities are sometimes seen as no-growth businesses, Barron's argues that infrastructure replacement projects, rate hikes, and dividend boosts make the sector look attractive. Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use